3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Bevacizumab
3
durvalumab
2
atezolizumab
2
Hepatectomy
2
tremelimumab
1
trastuzumab deruxtecan
1
pembrolizumab
1
Whole Genome Sequencing
1
Standard of Care
1
Specimen Handling
1
Radionuclide Imaging
1
Platinum
1
Ipilimumab
1
Immunotherapy
1
Immunoglobulin G
1
IMC-001
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Disulfides
1
Diathermy
1
Cisplatin
1
Cell- and Tissue-Based Therapy
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Immunotherapy
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled